The significant reductions in relative risk (RR) observed in our study—52% lower risk of cholelithiasis, 39% lower risk of cholecystitis, 34% lower risk of choledocholithiasis, and 61% lower risk of cholangitis—suggest that GLP-1/GIP receptor agonists may help modify key metabolic factors of biliary disease in high-risk populations. Here, GCG is linked to cholangitis.